Neuroprotective agents for clinical trials in Parkinson's disease: A systematic assessment

Neurology

Volumn 60, Issue 8, 2003, Pages 1234-1240

  Ravina, Bernard M ^a   Fagan, S C ^b   Hart, R G ^a   Hovinga, C A ^c   Murphy, D D ^a   Dawson, T M ^d   Marler, J R ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMANTADINE; ASCORBIC ACID; AZULENYL NITRONE; CAFFEINE; CREATINE; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ERYTHROPOIETIN; ESTROGEN; FOLIC ACID; GANGLIOSIDE GM1; GPI 1481; GPI 1485; LEVODOPA; MINOCYCLINE; MODAFANIL; NEUROPROTECTIVE AGENT; NICOTINE; PRAMIPEXOLE; RASAGILINE; REMACEMIDE; ROPINIROLE; SELEGILINE; TACROLIMUS; UBIDECARENONE; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; BRAIN PROTECTION; CLINICAL TRIAL; DEMENTIA; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSKINESIA; HUMAN; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SIDE EFFECT;

EID: 0037461309     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000058760.13152.1A     Document Type: Review

References (55)

1. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284:1931-1938.
2. Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet. 2002;359:1589-1598.
3. Mouradian MM. Recent advances in the genetics and pathogenesis of Parkinson's disease. Neurology. 2002;58:179-185.
4. McNaught KS, Mytilineou C, JnoBaptiste R, et al. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in the ventral mesencephalic cultures. J Neurochem 2002;81:301-306.
5. Jenner P, Schapira AH, Marsden CD. New insights into the cause of Parkinson's disease. Neurology 1992;42:2241-2250.
6. Zhang Y, Dawson VL, Dawson TM. Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol Dis 2000;7:240-250.
7. Marsden CD, Olanow WC. The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality. Ann Neurol 1998;44:S189-S196.
8. Sherer TB, Betarbet R, Greenamyre JT. Environment, mitochondria, and Parkinsons's disease. Neuroscientist 2002;8:192-197.
9. Rajput AH. Environmental causation of Parkinson's disease. Arch Neurol 1993;50:651-652.
10. Shoulson I. Where do we stand on neuroprotection? Where do we go from here? Mov Disord 1998;13(suppl 1):46-48.
11. Schmidt N, Ferger B, Neurochemical findings in the MPTP model of Parkinson's disease. J Neural Transm 2001;108:1263-1282.
12. Hennekens CH, Buring JE. Epidemiology in medicine. Boston: Little Brown and Co Boston 1987;30-44.
13. Schwarzschild MA, Chen JF, Ascherio A. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. Neurology 2002;58:1154-1160.
14. Ascherio A, Zhang SM, Hernan MA, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001;50:56-63.
15. 2A adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001;21:RC143.
16. 2A receptor blockade in experimental models of Parkinson's disease. J Neurochem 2002;80:262-270.
17. Shults CW, Beal MF, Fontaine D, et al. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology 1998;50:793-795.
18. Shults CW, Haas RH, Beal MF. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease. Biofactors 1999;9:267-272.
19. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-1550.
20. Tarnopolsky MA, Beal MF. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol 2001;49:561-574.
21. Matthews RT, Ferrante RJ, Klivenyi P, et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 1999;157:142-149.
22. Andreassen OA, Dedeoglu A, Ferrante RJ, et al. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol Dis 2001;8:479-491.
23. Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999;5:347-350.
24. Tabrizi SJ, Rajagoplan B, Styles P, et al. Creatine therapy for Huntignton's disease: clinical and phosphorous magnetic resonance spectroscopy findings in a one year pilot study. Move Dis 2002;17(suppl 5):S319.
25. Mayeux R, Marder K, Cote LJ, et al. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am J Epidemiol 1995;142:820-827.
26. Bower JH, Maraganore DM, McDonnell SK, et al. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999;52:1214-1220.
27. Baldereschi M, Di Carlo A, Rocca WA, et al. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. Neurology 2000;55:1358-1363.
28. Lee SJ, McEwen BS. Neurotrophic and neuroprotective actions of estrogens and their therapeutic implications. Annu Rev Pharmacol Toxicol 2001;41:569-591.
29. Behl C. Oestrogen as a neuroprotective hormone. Nat Rev Neurosci 2002;3:433-442.
30. Sherman FT. Hormone replacement therapy: the sudden halt of a clinical trial shakes long held beliefs. Geriatrics 2002;57:7.
31. Fadda E, Negro A, Facci L, et al. GM1 cooperates with brain-derived neurotrophic factor to protect dopaminergic neurons from 6-hydroxydopamine-induced degeneration. Neurosci Lett 1993;159(1-2):147-150.
32. Fusco M, Vantini G, Schiavo N, et al. Gangliosides and neurotrophic factors in neurodegenerative diseases: from experimental findings to clinical perspectives. Ann NY Acad Sci 1993;695:314-317.
33. Ferrari G, Batistatou A, Greene LA. Gangliosides rescue neuronal cells from death after trophic factor deprivation. J Neurosci 1993;13:1879-1887.
34. Schneider JS. GM1 ganglioside in the treatment of Parkinson's disease. Ann NY Acad Sci 1998;845:363-373.
35. Schneider JS, Roeltgen DP, Rothblat DS, et al. GM1 ganglioside treatment of Parkinson's disease: an open pilot study of safety and efficacy. Neurology 1995;45:1149-1154.
36. Schneider JS, Roeltgen DP, Mancall EL, et al. Parkinson's disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study. Neurology 1998;50:1630-1636.
37. Odaka M, Yuki N, Nobile OE, et al. Antibodies to GM1 (NeuGc) in Guillain-Barré syndrome after ganglioside therapy. J Neurol Sci 2000;175:96-106.
38. Tikka T, Fiebich BL, Goldsteins G, et al. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 2001;21:2580-2588.
39. Du Y, Ma Z, Lin S, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 2001;98:14669-14674:
40. Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome C release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417:74-78.
41. Wu DC, Jackson-Lewis V, Vila M, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl 1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J Neurosci 2002;22:1763-1771.
42. Du Y, Ma Z, Lin S. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci 2001;98:1469-1474.
43. Alarcon GS. Tetracyclines for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs 2000;97:1491-1498.
44. Gorell JM, Rybicki BA, Johnson CC, et al. Smoking and Parkinson's disease: a dose-response relationship. Neurology 1999;52:115-119.
45. Morens DM, Grandinetti A, Reed D, et al. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 1995;45:1041-1051.
46. Soto-Otero R, Mendez-Alvarez E, Hermida-Ameijeiras A, et al. Effects of (-)-Nicotine and (-)-cotinine on 6-hydroxydopamine-induced oxidative stress and neurotoxicity: relevance for Parkinson's disease. Biochem Pharmacol 2002;64:125-135.
47. Meshul CK, Kamel D, Moore C, et al. Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats. Exp Neurol 2002;175:257-274.
48. Gold BG, Nutt JG. Neuroimmunophilin ligands in the treatment of Parkinson's disease. Curr Opin Pharmacol 2002;2:82-86.
49. Maruyama W, Yamamoto T, Kitani K, et al. Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline. Mech Ageing Dev 2000;116:181-191.
50. Maruyama W, Asao Y, Carrillo M, et al. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 2002;24:675.
51. Rabey JM, Sagi I, Huberman M, et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 2000;23:324-330.
52. Schapira AH. Neuroprotection and dopamine agonists. Neurology 2002;58(suppl 1):S9-S18.
53. Marek K, Seibyl J, Shoulson I, et al. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson's disease progression. JAMA 2002;287:1653-1661.
54. Albin RL, Hichols TE, Frey KA. Brain imaging to assess the effects of dopamine agonists on progression of Parkinson's disease. JAMA 2002;288:311-312.
55. Ahlskog EJ. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 2003; In press.